UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HIV-1 Vaccine Development: Constrained Peptide Immunogens Show Improved Binding to the Anti-HIV-1 gp41 MAb

Biochemistry (Easton), 2003-03, Vol.42 (11), p.3214-3223

2003

Volltextzugriff (PDF)

Structural Analysis of the Epitope of the Anti-HIV Antibody 2F5 Sheds Light into Its Mechanism of Neutralization and HIV Fusion

Journal of molecular biology, 2003-07, Vol.330 (5), p.1101-1115

2003

Volltextzugriff (PDF)

Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like Particles Expressed in Yeast

The Journal of infectious diseases, 1997-11, Vol.176 (5), p.1141-1145

1997

Volltextzugriff (PDF)

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

Journal of Virology, 2003-06, Vol.77 (11), p.6305-6313

2003

Volltextzugriff (PDF)

Purification of Virus-like Particles of Recombinant Human Papillomavirus Type 11 Major Capsid Protein L1 from Saccharomyces cerevisiae

Protein expression and purification, 1999-12, Vol.17 (3), p.477-484

1999

Volltextzugriff (PDF)

Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation

Vaccine, 1994, Vol.12 (11), p.1021-1025

1994

Volltextzugriff (PDF)

Sensitive assays for hepatitis a antibodies

Journal of medical virology, 1993-11, Vol.41 (3), p.201-204

1993

Volltextzugriff (PDF)

In vitro T cell immune responses to the preS2 antigen of the hepatitis B virus envelope protein in preS2 + S vaccine recipients. Absence of cross-reactivity of subtypes at a major T cell recognition site

The Journal of immunology (1950), 1993-09, Vol.151 (6), p.3353-3360

1993

Volltextzugriff (PDF)

Vaccine-Induced Immunity in Baboons by Using DNA and Replication-Incompetent Adenovirus Type 5 Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

Journal of Virology, 2003-07, Vol.77 (13), p.7663-7668

2003

Volltextzugriff (PDF)

Saliva and Serum as Diagnostic Media for Antibody to Hepatitis A Virus in Adults and in Individuals Who Have Received an Inactivated Hepatitis A Vaccine

Clinical infectious diseases, 1995-04, Vol.20 (4), p.868-871

1995

Volltextzugriff (PDF)

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design

The Journal of biological chemistry, 2002-11, Vol.277 (48), p.45811-45820

2002

Volltextzugriff (PDF)

Analysis of a vaccine purification process by capillary electrophoresis

Journal of Chromatography A, 1991-10, Vol.559 (1), p.337-343

1991

Volltextzugriff (PDF)

The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults

Vaccine, 1997-07, Vol.15 (10), p.1157-1161

1997

Volltextzugriff (PDF)

Detection of antibody to the PreS2 sequence of the hepatitis B virus envelope protein using an immuno-ligand assay with a silicon sensor detection system

Journal of immunological methods, 1991-12, Vol.145 (1), p.19-26

1991

Volltextzugriff (PDF)

Anti-PreS2 antibody assay for evaluating immune responses among recipients of recombinant hepatitis B PreS2+S vaccine

Journal of medical virology, 1990-02, Vol.30 (2), p.146-150

1990

Volltextzugriff (PDF)

Anti-Hepatitis A in the General Population and in Hepatitis A Vaccinees Using Saliva and Serum as Diagnostic Media

Annals of the New York Academy of Sciences, 1993-09, Vol.694 (1), p.289-292

1993

Volltextzugriff (PDF)

Progress towards the development of a HIV-1 gp41-directed vaccine

Current HIV research, 2004-04, Vol.2 (2), p.193-204

2004

Volltextzugriff (PDF)

Duration of protection from clinical hepatitis A disease after vaccination with VAQTA

Journal of medical virology, 1996-07, Vol.49 (3), p.235-241

1996

Volltextzugriff (PDF)

Isolation of multiple biologically and chemically diverse species of epidermal growth factor

Peptides (New York, N.Y. : 1980), 1987-09, Vol.8 (5), p.877-885

1987

Volltextzugriff (PDF)

Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years

The Pediatric infectious disease journal, 1996-08, Vol.15 (8), p.687-692

1996

Volltextzugriff (PDF)

Viral Enhancement and Interference Induced in Cell Culture by Hepatitis A Virus: Application to Quantitative Assays for Hepatitis A Virus

Experimental biology and medicine (Maywood, N.J.), 1984-01, Vol.175 (1), p.84-87

1984

Volltextzugriff (PDF)

Human papillomavirus type II (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast

The Journal of infectious diseases, 1997-11, Vol.176 (5), p.1141

1997

Volltextzugriff (PDF)

Enhancement of α-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design

The Journal of biological chemistry, 2003-02, Vol.278 (7), p.5492

2003

Volltextzugriff (PDF)

Automated cytopathic effect (CPE) assays

Journal of biological standardization, 1983-01, Vol.11 (3), p.241,IN5-246,IN6

1983

Volltextzugriff (PDF)

Enhancement of [alpha]-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro. Implications for Vaccine Design

The Journal of biological chemistry, 2002-11, Vol.277 (48), p.45811-45820

2002

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(53)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(31)
Humans
(23)
Biological And Medical Sciences
(21)
Animals
(14)
Medical Sciences
(13)
Immunology
(12)
Fundamental And Applied Biological Sciences. Psychology
(9)
Virology
(9)
Adult
(8)
Female
(8)
Biochemistry & Molecular Biology
(7)
Infectious Diseases
(7)
Microbiology
(7)
Physical Sciences
(7)
Hepatitis A Virus
(6)
Male
(6)
Middle Aged
(6)
Aids Vaccines - Immunology
(5)
Antibodies, Monoclonal - Immunology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

HIV-1 Vaccine Development: Constrained Peptide Immunogens Show Improved Binding to the Anti-HIV-1 gp41 MAb

Structural Analysis of the Epitope of the Anti-HIV Antibody 2F5 Sheds Light into Its Mechanism of Neutralization and HIV Fusion

Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like Particles Expressed in Yeast

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

Purification of Virus-like Particles of Recombinant Human Papillomavirus Type 11 Major Capsid Protein L1 from Saccharomyces cerevisiae

Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation

Sensitive assays for hepatitis a antibodies

In vitro T cell immune responses to the preS2 antigen of the hepatitis B virus envelope protein in preS2 + S vaccine recipients. Absence of cross-reactivity of subtypes at a major T cell recognition site

Vaccine-Induced Immunity in Baboons by Using DNA and Replication-Incompetent Adenovirus Type 5 Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

Saliva and Serum as Diagnostic Media for Antibody to Hepatitis A Virus in Adults and in Individuals Who Have Received an Inactivated Hepatitis A Vaccine

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design

Analysis of a vaccine purification process by capillary electrophoresis

The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults

Detection of antibody to the PreS2 sequence of the hepatitis B virus envelope protein using an immuno-ligand assay with a silicon sensor detection system

Anti-PreS2 antibody assay for evaluating immune responses among recipients of recombinant hepatitis B PreS2+S vaccine

Anti-Hepatitis A in the General Population and in Hepatitis A Vaccinees Using Saliva and Serum as Diagnostic Media

Progress towards the development of a HIV-1 gp41-directed vaccine

Duration of protection from clinical hepatitis A disease after vaccination with VAQTA

Isolation of multiple biologically and chemically diverse species of epidermal growth factor

Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years

Viral Enhancement and Interference Induced in Cell Culture by Hepatitis A Virus: Application to Quantitative Assays for Hepatitis A Virus

Human papillomavirus type II (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast

Enhancement of α-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design

Automated cytopathic effect (CPE) assays

Enhancement of [alpha]-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro. Implications for Vaccine Design

Suchergebnisse filtern